drugset / Trial / NCT03957681
A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy and safety of KHK4827 in patients with systemic sclerosis who have moderate to severe skin thickening
Timeline
- Start
- 2019-05-23
- Primary completion
- 2020-10-16
- Completion
- 2025-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |